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for formulae (1) and (2). Such compositions exhibit 
activity as anticancer agents. 
and R is -H, -OH, -OCH3, or -OC2Hs and in-
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HETEROAROTINOIDS AS ANTICANCER AGENTS 
This is a continuation-in-part application of Ser. No. 
267,935 filed Nov. 7, 1988 now abandoned, which is a 
divisional of Ser. No. 48,586, filed May 5, 1987, now 
U.S. Pat. No. 4,833,254. 
BACKGROUND OF THE INVENTION 
1. Field oflnvention 
Henderson, and M. B. Sporn. The assays assess the 
ability of the test compound to prevent skin papillomas 
and carcinomas in mice or to prevent keratinization of 
cultured tracheal cells which frequently occurs when 
5 cells become premalignant. Further evidence on these 
points can be found in articles entitled "Chemopreven-
tion of Cancer with Retinoids" by M. B. Sporn and D. 
L. Newton, published in the Federation Proceedings, 
This invention relates to anticancer compositions. 
More specifically, the invention relates to certain novel 
heteroarotinoids and derivatives thereof. 
10 Vol. 38, pages 2528-2534 (1979) and "Structure-
Activity Relationships of Retinoids in Hamster Trach-
eal organ Culture" by D. L. Newton, W. R. Henderson, 
and M. B. Sporn, published in Cancer Research, Vol. 40, 
2. Description of the Prior Art 
Retinoids (vitamin A and derivatives thereof) consti- 15 
tute a group of compounds of enormous current inter-
est. The stimulus for this interest arises from observa-
tions that these compounds exhibit some antitumor 
activity and exert a preventive activity in models of 
chemical carcinogensis. Unfortunately, the use of natu- 20 
ral retinoids in cancer chemotherapy has some disad-
vantages. With the exception of trans-retinoic acid, 
natural retinoids are stored in the Hver, and blood levels 
of the materials do not increase proportionately even 
after massive doses. Thus, it is difficult to achieve a 25 
good distribution and to deliver a retinoid to specific 
target sites. In addition, acute toxicity has been associ-
ated with high dosages of natural retinoids. This "hy-
pervitaminosis A" limits clinical use of such com-
pounds. Modifications of the basic retinoid structure 30 
have been the subject of intensive effort recently. 
For example, systems with fused aryl rings have 
shown good potency in a tracheal assay. Such systems 
have been referred to as arotinoids and several papers 
on the subject have been published, such as in the Euro- 35 
pean Journal of Medicinal Chemistry, 1980, Vol. 15, 
pages 9-15, entitled "Arotinoids, A New Class of 
Highly Active Retinoids" by P. Loeliger, W. Bollag 
and H. Mayer. Synthesis and stereochemistry are dis-
cussed. A second more recent publication has peripher- 40 
ally related derivatives and is entitled "Fluorinated 
Retinoic Acids and Their Analogues". Synthesis and 
Biological Activity of Aromatic 6-Fluoro Analogues" 
by A. J. Lovey and B. A. Pawson. The article appeared 
in the Journal of Medicinal Chemistry, Vol. 25, pages 45 
71-75 (1982). A review of the entire area of biological 
activity of retinoids and related compounds has been 
published in the Journal of Medicinal Chemistry, Vol. 25, 
pages 3414-3425 (1980). Another test for potential anti-
cancer activity of retinoic acid derivatives has been the 
ornithine decarboxylase assay which has been reviewed 
recently in connection with an evaluation of some aro-
matic retinoic acid compounds. The article is entitled 
"Aromatic Retinoic Acid Analogues. Synthesis and 
Pharmacological Activity" by M. I. Dawson, R. Chan, 
P. D. Hobbs, W. Chao, and L. J. Schiff and was pub-
lished in the Journal of Medicinal Chemistry, Vol. 26, 
pages 1282-1293 (1983). The compounds of the present 
inventions were assayed using the tracheal organ cul-
ture procedure as well as assayed for the induction of 
differentiation of human (HL-60) promyelocytic cells. 
In an article by Waugh et al. "Synthesis and Charac-
terization of Selected Heteroarotinoids", Journal of 
Medicinal Chemistry, 1985, 28, 116, a series of 
heteroarotinoids based on the E isomer of 2-arylsub-
stituted parapecopenylbenyoates having a 4.4-dimethyl 
chromanyl-6-yl (or corresponding thiochromanyl or 
-1-oxothiochromanyl) bicyclic heteroatom containing 
ring structure as the substituent, the tracheal organ 
culture assay of selected heteroretinoids are compared 
with trans-retinoic acid for ability to reverse keratiniza-
tion in vitamin A deficient hamsters. In an article by 
Dawson et al. "Conformationally Restricted Reti-
noids", Journal of Medicinal Chemistry, 1984, 27, 1516, a 
series of conformationally restricted retinoids was syn-
thesized and acreened in two assays, Keratinization in 
tracheal organ culture (TOC) from vitamin A deficient 
hamsters and the inhibition of the induction of mouse 
epidermal ornithine decarboxylase (ODC) by a tumor 
promoter. It was found that the toxicity of these com-
pounds correlated with their activity in the TOC assay 
and that the heterocyclic analogues tended to be less pages 1269-1277 (1982). The title is "Retinoids at the 
Threshold: Their Biological Significance and Thera- 50 toxic. 
peutic Potential", by B. A. Pawson, C. W. Ehmann, L. 
SUMMARY OF THE INVENTION M. Itri, and M. I. Sherman. The first paper contains 
work which is the most closely related to the com-
pounds cited in this application in terms of preparation 
from ketones and conversion to the final product 55 
through a type of Wittig reaction. However, very few 
publications involving a heteroatom in the ring systems 
can be currently found and it is felt that the presence of 
the heteroatom makes a significant difference in the 
properties of the heteroarotinoids as compared to the 60 
arotinoids. 
According to the existing literature, some derivatives 
of the arotinoids have been found to posses useful bio-
logical activities. One type of test for therapeutic po-
tency is the antipapilloma test ( cited in the first article 65 
above) and the tracheal organ culture assay which is 
described in an article in the Journal a/Cancer Research, 
Vol. 40, 3413-3425 (1980) by D. L. Newton, W. R. 
The present invention involves novel (E) and (Z)-iso-
mers of chroman and thiochroman heterocyclic ana-
logues of retinoic acid and derivatives thereof wherein 
the I-position of the tetrahydronapthalene ring has been 
replaced by oxygen and sulfur, respectively. The pres-
ence of both the heteroatom and the bicyclic aryl group 
are felt to retain the desired activity at reduced toxicity. 
The invention further involves novel derivatives of the 
(E) and (Z)-isomers containing chromanyl and thio-
chromanyl structure wherein the derivative further 
contain a cyclic ether group representing a synthetic 
biological metabolite analog of retinoic acid which is 
felt to further reduce the toxicity. 
Thus, the present invention provides novel 




act as anticancer agents for the treatment of skin disor-
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ment of this object and the presence and fulfillment of 
other objects will be apparent upon complete reading of 
5 the specification and claims. 
BRIEF DESCRIPTION OF THE DRAWING 
FIG. 1 is a plot of the induction of differentiation of 
10 HL-60 cells as a function of retinoid concentration for 
trans-retinoic acid and two heteroaretinoids according 
to the present invention. 
15 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The novel heteroarotinoid compositions according to 
the preferred embodiments of the present invention are 
heteronuclear ring, organic compounds based on the 
generic structures designated below as compounds (1) 
20 through (6). As shown in these structural formulae, the 
!-position is occupied by the heteroatom which is either 
a sulfur or oxygen atom (for purposes of this invention 
the heteroatom is symbolized by X in the formulae). As 
25 structurally illustrated in the formulae the heteroatom 
appears in the ring portion of the arotionoid while the 
remaining portion of the structure is extremely reminis-
cent of the corresponding portion of the retinoid struc-
(5) 30 
ture (see formulae 1, 2, 3 and 4) or a potential biological 
metabolite of this portion of the retinoid structure (see 
formulae 5 and 6). The R in the formulae symbolizes a 
OAc 
OAc 





hydrogen (aldehyde form), methoxyl, ethoxyl or other 
oxyalkyl and substituted oxyalkyl group (ester form) or 
hydroxyl group (acid form). The OAc in formulae 5 and 
35 6 represents the acetate group. As exemplified later, the 
compositions of the present invention exhibit good bio-
logical activity with respect to accepted assays such as 
reversal of keratinization in the tracheal organ culture 
40 (TOC), induction of mouse epidermal ornithine decar-
boxylase (ODC) by a tumor promoter and induction of 
differentiation of human (HL-60) promyelocytic cells. 
Furthermore, they appear to be less toxic than the stan-
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for formulae (1) and (2). 65 
It is an object of the present invention to provide 
novel heteroarotinoids which are structurally related to 

























correspond to numerically identified formulae. The 
ketone or alcohol is then converted to a salt (12), (22), 
(29) or (30) with triphenylphosphine hydrobromide 
typically in methanol and subsequently reacted with an 
5 aldehyde (e.g., ester-aldehyde) in a reducing environ-
ment (e.g., BuLi ether) to produce the heteroarationoid 
structure (13), (23) or (31 ). The ester can then be modi-
fied to produce other desired derivatives. Various re-
crystallization and purification steps can be employed 
10 to achieve the desired degree of purity of compounds 
and isomers isolated. 
More specifically, reaction scheme A illustrates start-
ing with an ethyl 3-(phenylthio or phenyloxo)propion-
ate (7) and then converting this starting material to the 
15 corresponding 2-methyl-4-(phenylthio or phenyloxo)-2-
butanol (8) by the action of methylmagnesium iodide. 
The heteroatom containing ring of the correspond 
chroman or thiochroman structure (9) is produced by 
reaction of P20s in sodium-dried benzene. The known 
20 ketone structure (10) is produced in the nextstep by the 
reaction of acetyl chloride in a CS2 suspension of AlCl3. 
The ketone (10) is then reacted with vinyl magnesium 
bromide in tetrahydrofuran producing the vinyl alcohol 
(11). The corresponding phosphonium salt (12) is syn-
Typically, the compounds according to the present 
invention are or can be synthesized by one of the fol-
lowing generalized reaction schemes. These schemes 
involve the synthesis of the known ketones (10) and (27) 
or alcohol (21 ); the number in parenthesis as used herein 
25 thesized by reacting the vinyl alcohol (11) with triphen-
ylphosphine hydrobromide in methanol. The phospho-
nium salt (12) reacts in n-butyllithium with ethyl (E)-/3-
formylcrotonate by several alternate methods to se-
quential produce the ester form of the heteroarotinoid 
30 (13) which is then under control acidity isolated as the 
acid (14). The acid form can then be further converted 



































































..._ 0 0 




REACTION SCHEME B 
scribed scheme except a 4-bromanisole ( 18) or corre-
sponding thioanisole is reacted with /3-methallyl chlo-
ride (17) in concentrated H2SO4 to produce the chlo-
robutane (19) which is subsequently converted to a 
20 five-member heteroatom containing ring. This is ac-
complished in the second step by the use of pyridine 
hydrochloride and quinoline with heat producing the 
bromine substituted dimethybenzofuran and corre-
sponding thiofuran (20). This in tum is converted to the 
25 corresponding Grignard reagent by use of Mg in dry 
THF which is treated with acetaldehyde to give the 
alcohol (21) reminiscent of the previous formation of 
ketone (10) followed by vinyl alcohol formation (11). 
The alcohol (21) is then converted to the corresponding 
30 triphenylphosphonium bromide salt (22) analogous to 
~OH 
\✓ 
· the previous compound (12) of reaction scheme A. The 
triphenylphosphonium bromide salt can then be reacted 
in the presence of butyllithium and the appropriate 
unsaturated ester-aldehyde to produce the heteroaroti-
35 noid esters (23) of the present invention. Further purifi-
cation, isolation and conversion to other derivatives can 
be performed on esters (23) as previously illustrated in 
scheme A. 
40 
REACTION SCHEME B 
{17) + (1'8) 
45 




(19) 50 In reaction scheme C, the first step is essentially the 
I ~yridine hydrochloride 
~ Quinoline, Heat 
~Br 
\✓ 
I;· Mg/THF f. H3CCHO 
same as the first step of scheme A except the reactant 
(24) is a methyl propionate rather than an ethyl propio-
nate. The second step involves closing the heteroatom 
containing ring by use of anhydrous aluminum trichlo-
55 ride in nitromethane to produce the benzopyran or 
analogous benzothiopyran (26) structure. The ketone 
(27) is then produced by further addition anhydrous 
aluminum trichloride in the presence of acetyl chloride. 
(20) Lithium aluminum hydride in dry ether is used in the 
60 next step to reduce the ketone (27) to the alcohol (28) 
without addition of the vinyl group of scheme A. The 
alcohol (28) is then treated with triphenylphosphine 
hydrobromide forming the phosphonium salt (29). This 
precursor phosphonium salt (29) is then reduced in an 
65 n-butyllithium/hexane solution followed by the addi-
tion of 5-acetoxymethyl-2-furaldehyde producing the 
acetoxymethyl furanyl propene structure (31). 
11 

















(25) 15 (3 !) OAc 
20 
In order to further illustrate the general synthesis of 
the heteroarotinoids according to the present invention; 
25 their respective preparation and isolation as a purified 
(26) biologically active heterocycle; and their activity in the 
ornithine decarboxylase assay as well as the HL-60 
human leukemic cell line, the following sequence of 




Preparation of Ethyl 3-(Phenylthio)Propionate (32) 
To a solution of 12.12 g (0.11 mol) of thiophenol, 
35 10.01 g (0.10 mol) ethyl acrylate, 20 mL of HCCJ3 at 0° 
C. in a 100-mL, round-bottom flask, 0.50 mL of triethyl-
amine was added under N2. The ice bath was removed 
after the addition of triethylamine and the solution was 
4-0 allowed to stir at room temperature for 3 hours. The 
resulting solution was idluted with 150 mL of ether and 
washed with 10% NaOH, H2O, and saturated NaCl 
solution. The mixture was dried (Na2SO4, overnight) 
and the solvents were removed. Vacuum distillation 
45 gave 19.36 g (92.1 % ) of ethyl 3-(phenylthio )propionate 
as a clear, colorless liquid: bp 112°-115° C./0.2 mm 
[literature reports 117° C./2.5 mm; see K. Iwai, H. 
Kosugi, A. Miyazaki, and Huda, Synthetic Communica-
(28) 50 tions, 6, 357 (1976)]; IR (neat) 1740 cm-I (C=O); IH 
NMR (DCCIJ) 61.14 [t, 3H, CO2CH2C!!3], 2.54 [t, 2H, 
CH2CO2CH2CH3], 3.10 [t, 2H, ArSCH2], 4.06 [q, 2H, 
C02CH2CH3], 7.13-7.32 [m, 5H, A7H]; 13C NMR 
(DCC½) ppm 13.6 [CO2CH2CH3], 28.3 [ArSCH2], 33.8 
55 [CH2CO2CH2CH3], 60.0 [CO2CH2CH3], 125.8, 128.4, 
129.3, 134.8, 170.9 [f=O]. Both hydrogen and carbon-
13 NMR spectra shifts were measured from tetrame-
thylsilane (TMS) standard on a Varian XL-300 spec-
(29) 60 
65 
trometer confirming the correct hydrogen distribution 








To a freshly prepared solution of methylmagnesium 
iodide [42.59 g, (0.30 mo!) of methyl iodide, 7.41 grams 
(0.305 g at) of magnesium] in 75 mL of ether, 21.03 g 5 
(0.10 mo!) of ethyl 3-(phenylthio)propionate in 25 mL 
of ether was added dropwise under N2 in a 500-mL, 
round-bottom flask equipped with a condenser and a 
nitrogen inlet. The solution was boiled for 1 hour and 
allowed to stir at room temperature for 10 hours. The 10 
resulting solution was neutralized with dilute H2SO4; 
the ether layer was separated, and the aqueous layer 
was extracted with ether (3X75 mL). The ether layers 
were combined and dried (Na2SO4, overnight). Solvent 
was evaporated and vacuum distillation of the residual 15 
oil gave 19.02 g (78.5%) 2-methyl-4-(phenylthio)-2-
butanol as a clear colorless liquid: by 106° -107.5° 
C./0.15 mm [literature reports 110°-113° C./0.17 mm, 
see F. Montanari, R. Daniel, H. Hogeveen, and G. Mac-
cagnani, Tetrahedron Letters, 2685 (1964)]; IR (neat) 20 
3400 cm- 1 br (OH); lH NMR (DCCl3) ol.18 [s, 6H, 
(CH3)2C], 1.76 [m, 2H, ArSCH2CH2], 2.74 [hr s, lH, 
OH] 2.95 [m, 2H, ArSCH2], 7.10-7.36 [m, SH, ArH]; 
13C NMR (DCCIJ) ppm 28.6 [ArSCH2CH2], 29.3 
[(CH3)2C], 42.7 [ArSCH2CH2], 70.7 [(CH3)2C], 125.9, 




mo!) in a 500-mL, round-bottom flask equipped with a 
condenser and nitrogen inlet. The resulting yellowish-
orange mixture was allowed to stir for 10 hours at room 
temperature; 80 mL of ice water was added and the two 
layers separated. The aqueous layer was extracted with 
ether (3 X 50 mL); the ether layers were combined and 
dried (Na2SO4, 6 h). After evaporation, the resulting 
light yellow oil was vacuum distilled to give 10.83 
grams (87.6%) of 6-acetyl-4,4-dimethylthiochroman as 
a yellowish viscous oil: bp 168°-173° C./1.0 mm; IR 
(neat) 1680 cm- 1; 1H NMR (DCCl3) ol.31 [s, 6H, 
(CH)3)2C], 1.89 [m, 2H, ArSCH2CH2], 2.52 [s, 3H, 
CHJC=0]3.01 [m, 2H, ArSCH2Cifi], 7.11 [d, lH, 
J~8.l Hz, H(8)], 7.57 [dd, lH,J=l.7 Hz, J=8.l Hz, 
H(7)], 8.00 [d, lH, J = 1.7 Hz, H(5)]; 13C NMR ppm 23.1 
[ArSCH2CH2] 26.2 [CH3C=O], 29.8 [(CH3)2C], 32.8 
[(CH3)2C], 36.8 [ArSCH2CH2], 125.8, -126.2, 132.9, 






To a freshly prepared solution of vinylmagnesium 
bromide; [7.65 g (0.0715 mo!) of vinyl bromide and 1.75 
grams (0.0720 g at) of magnesium in 40 mL of dry 
THF], 10.5 g (0.0477 mo!) 6-acetyl-4,4-dimethylthio-4,4-Dimethylthiochroman or 
3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran (34) 35 chroman in 25 mL of THF was added dropwise under 
N2 in a 200-mL, round-bottom flask equipped with a 
condenser and nitrogen inlet. The solution was then 
boiled for 1 hour and allowed to stir for 10 hours at 
A mixture of 15.00 grams (0.076 mo!) of 2-methyl-4-
(phenylthio)-2-butanol, 12.75 grams of H3PO4, 27.0 
grams (0.190 mo!) of P2Os [this is added in three equal 
portions every 8 h] and 60 mL of sodium-dried benzene 40 room temperature. Saturated NH4Cl was added in 
was boiled under Nz for 24 hours in a 250-mL, round- 1-mL portions until the solution was slightly acidic (pH 
bottom flask equipped with a condenser and nitrogen approx. 6.8), and 100 mL of ether was added and the 
inlet. The resulting, cooled heterogeneous mixture was two layers separated. The aqueous layer was extracted 
separated and the P2Os layer was extracted with ether. with ether (4X 100 mL) and the ether extracts were 
The combined organic layers were washed with H2O, 45 combined with the original organic layer. The com-
brine, dried with Na2SO4 (4 h). Evaporation and vac- bined organics were washed with 50 ml of H2O and 50 
uum distillation gave 11.68 grams (86.0%) of 4,4-dime- mL of brine and was then dried (Na2SO4, 4 h). After 
thylthiochroman as a clear colorless liquid: bp 75° -82° evaporation, the resulting oil was used without further 
C./0.l mm; 1H NMR (DCCl3) ol.29 [s, 6H, (C!!3)2C] purification; IR (neat) 3200-3600 cm-1 (OH); IH 
1.92 [m, 2H, ArSCH2C!!2] 3.00 [m, 2H, ArSC!!2CH2] 50 (DCCJ3) ol.32 [s, 6H, (CH3)2C], 1.95 [m, 2H, 
6.90-7.32 [m, 4H, Ar-!!]; 13C NMR (DCCl3) ppm 22.8 ArSCH2CHz], 2.11 [bs, rn-;- OH], 3.00 [m, 2H, 
[ArSf_H2CH2], 29.9 [(f_H3)2C] 32.6 [(CH3)f_], 37.4 ArSCHzCH2], 5.14 [dd, IH, J =2J5 Hz, J = 10.5 Hz, 
[ArSCH2f_H2], 123.7, 125.7, 126.l, 126.2, 131.5, 141.5. CH==CHz(cis)], 5.30 [dd, lH, J =2.0 Hz, J = 15.0 Hz, 
CH==CH2(trans)], 6.16 [dd, lH, J = 10.5 Hz, J = 15.0 Hz, 
<34) 55 CH==CH2], 7.05 [d, lH, J = 8 Hz, H(8)], 7.12 [dd, lH, 
J ~Hz, J =8 Hz, H(7)], 7.52 [d, lH, J =2 Hz, H(8)]; 13C 
(DCCl3) ppm 22.9 [ArSCH2CH2], 29.1 [CH3COH], 30.2 
[(CH3)2C], 33.1 [(CH3)2C], 37.3 [ArSCH2CH2], 74.5 
60 




A solution of 10.0 g (0.056 mo!) of 4,4-dimethylthio- 65 
chroman and 4.4 g (0.056 mo!) of acetyl chloride in 150 
mL of CS2 was added dropwise over a 45-minutes per-
iod to a stirred CS2 suspension of AICl3 (11.22 g, 0.084 
(36) 
15 
Phosphonium Salt (37) 
4,977,276 
To a suspension of 10.78 grams (2.28 mmol) of tri-
phenylphosphine hydrobromide in methanol (20 mL) 
was added the previously prepared alcohol ( ) in a 100- 5 
mL, round bottom flask and stirring was initiated at 
room temperature and continued for 9.5 hours. Metha-
nol was removed (vacuum) from the clear solution and 
ether (approx. 50 mL) was added and crystrallization 
occurred within a short time. After standing overnight, 10 
0.91 g (63.0% from the vinyl alcohol) of white crystals 
were collected, recrystallized (methanol/ether) and 
dried (vacuum): mp 268.5°-269.5° C. dee.; 1H NMR 
(DCC!}) 1.26 [s, 6H, (CH3)2C], 1.63 [d, 3H, J =4.0 Hz, 
CH3C=CH], 1.93 [m, 2H, ArSCH2CH2], 3.02 [m, 2H, 15 
ArSCH2CH2], 4.89 [dd, 2H, J=8.0 Hz, J=l.51[JPH], 
C=CHCH2P], 5.6 [tq, lH, J =4.0 Hz, J =8.0 Hz, 
CH3C=CHCH2P], 6.85[dd, lH, J=2.0 Hz, J=8.1 Hz, 
H(7)], 7.00td, lH, J=8.1 Hz, H(8)], 7.17[d, lH, J=l.7 
Hz, H(5)], 7.66-8.00 [m, 15H, P(ArH)3]; 13C NMR 20 
(DCCl3) ppm 17.0 [CH3C=CH], 23.0[ArSCH2CH2], 
25.4 [d, J =49 Hz [TCP], C=CHCH2], 30. lTCH3)2C], 
33.0[(CH3)2C], 37.4 [ArSCH2CH21110.2 1103, 117.6, 
118.8, 123.4-:- 123.9, 126.4, 130.2, 130.4 132.1, 133.9, 
134.1, 135.0, 138.0, 138.1, 141.9, 145.4, 145.6; 3lp 25 
(DCCl3) ppm 21.6, Anal. Calcd for C33H34SPBr: C, 





CHCO2H], 6.59 [d, lH, 1 = 12 Hz, ArC(CH3)C!!], 7.09 
[d, lH, 1=7 Hz, H(8)], 7.10 [dd, lH, 1=12 Hz, 1=15 
Hz, CH-CH==CH], 7.21 [dd, lH, J=2 Hz, J=7 Hz, 
H(7)], 7.52 [d, lH, 1 =2 Hz, H(5)]; 13C NMR (DCCl3) 
ppm 13.8 [CH3], 16.1 [CH3], 23.0 [ArSCH2CH2], 30.1 
[(CH3)2C], - 33.0 [(CH3)2C], 37.5 [ArSCH2CH2], 
118.3[CHC02H], 123.3 [C(7)], 123.6 [C(5)], 125.4 
[ArC(CH3)_gHJ, 126.4 [C(8)], 131.5, 131. 7 
[CH-CH==CH], 135.4 [CHC(CH3) CHCO2H], 138.1, 
140.2, 141.7, 154.0 [f(CH3)CHC02H], 170.8[fO2H]. 
7-[ 4.4-Dimethylthiochroman-6-yl]-3, 7-dimethyl-2,4, 6-
heptatrienoic acid (38) Method 2 
To a suspension of 3.56 g (0.0062 mol) of/phos-
phonium salt in ether/THF (50 mL 2:3 ether/THF) was 
added dropwise n-butyllithium in hexane (4.01 mL, 
l.55M., 0.1006 mol) at room temperature under N2 in a 
100-mL, round bottom flask equipped with a condenser 
and nitrogen inlet. The resulting, dark orangish-red 
solution was cooled to - 78° C. and 0.90 g (0.0062 mo!) 
of ethyl (E)-B-formylcrotonate in 10 mL of ether was 
added dropwise in the dark. The solution was stirred for 
10 minutes and wanned to -43° C. (10 min); a second 
equivalent of n-butyllithium (4.01 mL, 1.55M, 0.00621 
mol) in hexane was added and the resulting orange 
solution was allowed to stir for 20 min. This solution 
was treated with 0.25 g (0.0686 mol) of HCl(g) in the 
THF followed by the addition of 0.69 g (0.093 mol) of 
t-butyl alcohol and 1.04 g (0.093 mol) potassium t-
butoxide. The yellowish solution was allowed to warm 
to room temperature with stirring for 70 minutes; it was 
7-[ 4.4-Dimethylthiochroman-6-yl]-3, 7-dimethyl-2. 
4,6-heptatrienoic acid (38) Method 1 
35 then diluted with 100 mL of hexane, filtered and evapo-
rated (vacuum) to give a yellow oil. The resulting oil 
was added to a solution of 4.5 g (0.0802 mol) of KOH in 
aqueous ethanol (50 ml of 4:1 ethanol/H2O) and the 
solution was boiled in the dark for 30 min. The reddish To a suspension of 5.82 g (0.01015 mo!) of phospho-
nium salt 37 in mL of ether, was added dropwise n- 40 
butyllithium (6.76 mL, 1.50M. 0.010 mo!) at room tem-
perature under N2. The resulting, dark read solution 
was cooled to - 78° C., and 1.44 g (0.01015 mo!) of 
ethyl (E)-,B-formylcrotonate in 10 mL of ether was 
added dropwise in the dark. The solution is allowed to 45 
warm to room temperature and stir for 24 hours. The 
resulting orangish-yellow suspension was diluted with 
25 mL of hexane and filtered. The clear solution was 
washed with water (2X50 mL), passed through anhy-
drous Na2SO4 and evaporated (vacuum) to give a yel- 50 
low oil. The oil was dissolved in 50 mL of absolute 
ethanol and added to a mixture of 2.3 g KOH in 10 mL 
of H2O under N2. The new ethanol and added to a 
mixture of 2.3 g KOH in 10 mL of H2O under N2. The 
new solution was boiled at reflux for 1 hour and the 55 
reddish mixture was allowed to cool to room tempera-
ture. The solution was acidified with 50% acetic acid 
which formed a yellow suspension after extraction with 
ether (3X 100 mL) and evaporation (vacuum) gave a 
yellow solid. The solid was fractionally recrystallized 60 
(absolute ethanol) and dried under high vacuum at 
room temperature for 36 hours in the dark, to give 1.50 
g [45.0% from the precursor phosphonium salt] of 
heteroarotinoic acid (38) as yellow needles: m.p. 
204°-204.5° C. dee; 1H NMR (DCCl3) 81.37 [s, 6H, 65 
(CH3)2C], 1.98 [m, 2H, ArSCH2CH2 2.25 [s, 3H, CH3], 
2.42 [s, 3H, CH3] 3.06 [m, 2H, ArSCH2CH2 5.86 [br s, 
lH, C!! ==CO2H], 6.44 [d, lH, 1 = 15 Hz, C!!C(CH3) 
solution was cooled (RT), treated with 5.0 g of NaCl 
and extracted with 100 mL ether. The ether layer was 
extracted with water (4X50 mL), and the combined 
aqueous layers were acidified slowly with dilute 
H2SO4. At the neutralization point, solid began to form; 
the aqueous yellow suspension was extracted with ether 
(2 X 75 mL). The yellow ether layer was dried (Na2SO4) 
and evaporated (vacuum) to give a yellow solid. After 
fractional recrystallization (absolute ethanol), 0.88 g 
[43.1 % from the precursor salt] of acid (38) was ob-
tained as yellow needles with a mp of 204°-204.5° C. 
dee. 1H NMR (DCCl3) 81.37 [s, 6H, (CH3)2C], 1.98 [m, 
2H, ArSCH2CH2], 2.25 [s, 3H, CH3], 2A2 [s, 3H, CH3] 
3.06 [m, 2H, ArSCH2CH2], 5.86 [br s, lH, CH==C02H], 
6.44 [d, lH, 1=15Hz, C!!C(CH3) CHC02H], 6.59 [d, 
lH, J=12 Hz, ArC(CH3)CH], 7.09 [d, lH, J=7 Hz, 
H(8)], 7.lO[dd, lH, J-;;;;;12 Hz, J=15 Hz, 
CH-CH==CH], 7.21 [dd, lH, J =2 Hz, 1 =7.8 Hz, 
H(7)], fi2 [d, lH, 1 =2 Hz, H(5); 13C NMR (DDCl3) 
ppm 13.8 [CH3], 16.1 [CH3)2C], 23.0 [ArSCH2CH2], 
30.1 [(CH3)2C], 33.0 [(CH3)2C], 37.5 [ArSCH2CH2], 
118.3 (CHC02H], 123.3 [C(7)], 123.6[C(5)], 125.4 
[ArC(CH\)CH], 126.4 [C(8)], 131.5, 131. 7 
[CH-CH~H], 135.4 [CHC(CH3)CHCO2H], 138.1, 
140.2, 141.7, 154.0 [C(CR})CHC02H], 170.8 [CO2H]. 
Anal. Calcd for C20H2402S: C, 73.13; H, 7.36; S, 9.76. 











heptatrienoate ( 40) 
To a suspension of 0.5030 g (0.00153 mo!) of trans-
heteroarotinoic acid lb in 8 mL of dry ether was added 
0.1420 g (0.184 mL, 0.00180 mo!) of freshly distilled 
pyridine in a 50-mL, round-bottom flask equipped with 
Ethyl a condenser and nitrogen inlet, and the suspension was 
10 cooled to -10° C. A solution of 0.2005 g (0.123 mL, 7-[4,4-Dimethylthiochroman-6-yl]-3,7-dimethyl-2,4,6- 0.00169 mol) of SOCh in ether (1 mL) was added and 
heptatrienoate (39) the new solution was stirred at room temperature for 1 
To a suspension of 0.5030 g (0.00153 mol) of trans- hour. The resulting dark red solution was filtered and 
heteroarotinoic acid (38) in 8 mL of dry ether was cooled to -20° C.; 0.1420 g (0.184 fmL, 0.00180 mol) of 
added 0.145 mL 0.0018 mol) of freshly distilled pyridine 15 pyridine was added. Then 0.2963 g (0.00155 mol) of 
under N2, and the mixture was cooled to -10° C. in a N-2-hydroxyethylphthalimide in 8 mL of dry DMF was 
50-mL, round bottom flask equipped with a condenser introduced at room temperature and the solution was 
and nitrogen inlet. A solution of 0.1005 g (0.123 mL, allowed to stir for 10 hours. The resultant yellow solu-
0.00169 mol) of SOCh in ether (1 mL) was added and tion was diluted with ether (25 mL) and washed with 
stirring was continued at room temperature for I hour. 20 water (5 x 60 mL); and the ether layer was dried (Na2-
The resulting dark red solution was filtered and cooled so4, overnight). The solvent was removed (vacuum) 
to -20° C. Then 0.1420 g (0.145 mL, 0.00180 mol) of and the resulting yellow solid was chromatographed on 
pyridine was added and 0.21 g (0.266 mL, 0.00459_ m_ol) silica gel using DCCIJ. The phthalimide-substituted 
of dry ethanol was introduced all at once and st1rnng heteroarotinoid (40) [0.2731 g (35.6%)] was a yellow 
was maintained at room temperature for 3 hours. The 25 solid: mp 64°-65° C.; IR (KBr) 1760-1710 cm-1; 1H 
yellow solution was diluted with 25 mL of ether and the NMR (DCCb) ol.36 [s, 6H, (C!!3)2C], 1.98 [m, 2H, 
new solution was washed with water (4 X 30 mL); the ArSCH2CSH2], 2.24 [s, 3H, C!!3], 2.34 [s, 3H, C!!3], 
ether layer was dried (Na2SO4, 1 h). The solvent was 3.06 [m, 2H, ArSCH2CH2], 4.03 [t, 2H, CO2CH2C!!2], 
removed (vacuum) and the resulting yellow oil was 4.40 [t, 2H, COzCH2C!!2], 5.78 [s, lH, 
chromatographed on silica gel using hexane/ether 30 CHco2CHzCH2], 6.38 [d, lH, J = 15 Hz, 
(15:1) with the silica gel retaining the trans- CRC(CHJCHCOzCH2], 6.55 [d, IH, J = 12 Hz, 
heteroarotinoic acid (38). The ethyl ester (39) [0.4923 g, ArC(CHJ)CH], 7.03 [dd, IH, J = 12 Hz, J = 15 Hz, 
(88.1 % )] was obtained as a viscous yellow oil; 1 H NMR CH-CH==CH], 7.08 [d, IH, J = 8 Hz, H(8)], 7.18 [dd, 
(DCCl3) ol.30 [t, 3H, CO2CH2C!!3], 1.36 [s, 6H, J =2 Hz-;-J =8 Hz, H(7)], 7.48 [d, H, J =2 Hz, H(5)], 7.75 
(CH3)2C], 1.96 (m, 2H, ArSCH2C!!2], 2.22 [s, 3H, C!!3] 35 [m, 2H], 7.80 [m, 2H]; i3C NMR (DCCL3) ppm 13.9 
2.38 [s, 3H, CH3], 3.14 [m, 2H, ArSC!!2]CH2], 4.19 [q, [CH3], 16.2 [CH3], 23.1 [ArSfH2CH2], 30.2 [(fH3)2C], 
2H, CO2CH2CH3], 5.82 [s, IH, C!!COOEt], 6.39 [d, 33.1 [(CH3)2C], 37.1 [CO2CH2fH2], 37.6 
IH, J=l5Hz, C!! C(CH3)CHCO2Et], 6.55 [d, IH, [ArSCHzCH2], - 60.8 [CO2fH2CH2], 117.9 
J = 12 Hz, ArC(CH3)C!!], 7.03 [dd, IH, J = 12H], 7.07 [CHCOzCH2cH2], 123.3 123.4 [C(7)], 123.6 [C(5)], 
[d, IH, J=8 Hz, H(8)], 7.18 [dd, IH, J=2 Hz, J=8 Hz, 40 125.5 [CH-CH=CH], 126.5 [C(8)], 131.4, 131.8, 132.0 
H(7)], 7.48[d, IH, J=2 Hz, H(5)]; 13C NMR (DCCb) [CH-CH=CH], 134.0, 135.4 (CH-CH==fH], 138.2 
ppm 13.8 [CH3], 14.3 [Ch2fh3] 16.2[fH3], 23.1 140.1, -141.8, 153.5 [C(CH3)CHCO2CH2], 166.6 
[ArSfH22CH2], 30.1 [(fH3)2C], 33.1 [(CH3)2f], 37.6 co2cH2CH2], 168.0 [CH2N(f=0)2]; Anal. Calcd for 
. [ArSCH2CH2], 59.6 [CH2CH3], 118. 7 [fHCO2Et], c30H31No4s: C, 71.83; H, 6.23; N, 2. 79. Found C, 
123.4 [C(7)], 123.6 [C(5)T, 125.5 [CH-CH=CH], 126.4 45 71.47; H, 6.31; N, 2.76. 
[C(8)], 131.1 [CH-CH=CH], 135.5 [CH-CH==fH], 
138.2, 139.9, 141.7,-152.3 [f[CH3)CHCO2Et], 167.1 






..._ 0 0 
2-(2-Methoxy-5-bromophenyl)-2-methyl-1-chloropro-
pane (41) 
Concentrated H2SO4 (4 mL, 7.6 g, 0.077 mol) was 
added dropwise under N2 to stirred 4-bromoanisole 
(44.0 g, 0.235 mol). After warming the mixture ~o 36° C. 
(warm water bath), distilled .B-methallyl chlonde (21.5 .... 0 
65 mL, 20.0 g, 0.221 mol) was added dropwise to the 
stirred mixture in 4 equal portions over a period of 1.6 
hours ( 4 X 0.4 h). During the addition of the .B-methallyl 
chloride, the temperature of the mixture was maintained 
4,977,276 
19 
at 35° -44 ° C. (using a warm water bath). After the addi-
tion of the ,B-methallyl chloride was complete (1.6 h), 
the reaction mixture became solid and was allowed to 
stand [l hour over water bath (29° -32° C.), 2 hours at 
room temperature]. The wet solid was partitioned be- 5 
tween H2CC}z (500 mL) and H2O) (175 mL). The or-
ganic layer was separated and then washed with 5% 
aqueous NaHCO3(175 mL) and H2O [175 mL, 5 mL of 
brine being added to destory an emulsion which 
formed]. After drying (MgSO4, 36 h), the organic solu- 10 
tion, the solvent was removed, and the solid residue was 
vacuum distilled to remove a lower boiling liquid (bp 
42° C./0.15 mm -95° C./0.07 mm, mostly 4-
20 
ppm 27.3 [C(CH3)2] 84.7 [OCH2]; Ar-C[l 11.2, 112.2, 




1-(2,3-Dihydro-3,3-dimeth y 1-5-benzofurany !)ethanol 
(43) 
bromoanisole). A solution of the remaining solid residue A mixture of the precursor ether (0.21 g. 0.9 mmol), 
in H2CC!z was treated with decolorizing charcoal. 15 Mg turnings (1.0 g 0.041 g at) and dry THF (2 mL) was 
Evaporation of the H2CCl2 gave a tan solid which was heated (heat gun) under N2 until the mixture turned 
recrystallized (twice, heptane) and dried [traces of sol- cloudy (ca 15 min). Dry THF (15 mL) was added to the 
vent were removed (high vacuum)] to give the aryl mixture which was then heated to reflux. A solution of 
ether as a white crystalline solid (37.7 g, 61.5%); mp ether (42) (2.92 g, 12.9 mmol) in dry THF (25 mL) was 
87.8° -89.1 ° C. [(iterature r~ports 82° -8~
0
• C.; s~e ~- 20 added dropwise to the vigorously stirred mixture over a 
Gates, D. Baldwm, C. A. Wilson and J. Gillion (Fison s period of 0.75 hours. After vigorous stirring at reflux 
Ltd.), U.S. Pat. No. 4,333,759; Chem Abstr. 1~82, 97, for 2.75 hours, another 0.25 g (0.010 g at) of Mg turn-
215978 p]. _Another 3.4 g (5-5%) co?ld be obtamed by ings were added. The new mixture was stirred at reflux 
the followmg procedure. Evaporation of the mother ,. 0 75 h d 'th t 1 h t " 0 5 h I. I'd h' h d' 1 d • H CCI ,or . our an wi no ex erna ea ,or . ours. iquors gave a so i w ic was isso ve m 2 2- ?5 U I' h . 5• 100 C (' 1 Partial decolorization (charcoal) of the H2CC}zsolution - pon coo m~ t e mixture t? -:- to - · ice-sat 
followed by evaporation gave a solid residue which was bath), a sol~uon of freshly distilled acetaldehyde (~.O g, 
recrystallized (twice heptane)· the yield of ether was 0.045 mo!) m dry THF (20 mL) was added dropw1se to 
41.1 grams (67%). '1R(KBr) '1246 cm-l(C-O); IH the vigorously stirred mixture over a period of 0.7 
NMR (DCCI)) ol.43 [s, 6H, C(CH3)2], 3.84 (s, 3H 30 hours. This reaction mixture was stirred in an ice-salt 
OCH3), 3.96 (s, 2H, OCH2), 6.78-(d, lH, Ar-H), bath (-5° to -10° C.) for 1.5 hours, after which time a 
7.32-7.41 (m, 2H, Ar-H); Tic NMR (DCCb) ppm 23:8 solution of acetaldehyde (0.9 g, 0.020 mo!) in dry THF 
[C(CH3)2], 40.4 [C(CH3)2], 53.3 [CH2Cl], 55.3 [OCH3]; (5 mL) was added dropwise (over a period of about 0.2 
Ar-C[l 13.1, 130.6, 131.2, 135.4, 157.2] Both hydrogen h) and the new mixture was stirred 0.3 hours. With 
andcarbon-13 NMR spectral shifts were measured from 35 continued cooling (-5° to -10° C.), saturated aqueous 
tetramethylsilane (TMS) on a Varian XL-300 NMR NH4CI (3 mL) was added and the excess Mg turnings 
spectrometer confirming the correct hydrogen distribu- were removed by filtration. Saturated aqueous NH4CJ 
tion and carbon atoms assignments. (10 mL) and ether rinses (of glassware and Mg turnings, 
60 mL) were added to the filtrate. After separating the 
(41) 40 organic layer, the aqueous phase (pH~8) was acidified 
(pH 6.5 to 7) with saturated aqueous NH4Cl (15 mL) 
and 4% H2SO4 (14 mL). The aqueous solution was 
extracted with ether (5 X 40 mL) and ether (90 mL) was 
added to the combined organics. The organic solution 
5-Bromo-2,3-dihydro-3,3-dimethylbenzofuran (42) 
45 was washed with saturated aqueous NaHCO3 (75 mL) 
and brine (50 mL). After drying (MgSO4) the solution, 
the solvent was removed, and the residual oil was chro-
matographed through a circular silica gel plate ( 4 mm) A mixture of 2-(2-methoxy-5-bromophenyl)-2-meth-
yl-l-chloropropane (ether above; 12.60 g 0.045 mo!), 
pyridine hydrochloride (23.7 g 0.205 mo!), and quino- 50 
line (22.9 g 0.177 mo!) was heated to 164° C. (boiling 
isobutylbenzene bath) under N2 with stirring over a 
period of 0.6 hours. After stirring at reflux (164°-167° 
C.) for 3 hours, the mixture was partitioned between 
ice-cold 6N HCI (225 mL). The organic layer was sepa- 55 
rated and the aqueous layer was extracted (ether 200 
mL). After drying (MgSO4, overnight) the combined 
organics, the solvent was evaporated and the residual 
spun by a Chromatotron (Model 7.924T, Harrison Re-
search, 840 Moana Court, Palo Alto, Calif.). Half of the 
product was eluted with ether/petroleum ether (bp 
50°-110° C.) 20:1, 8:1, then 4:1 and then the same sol-
vent system was used to elute the other half. In both 
separations, the 4: 1 ratio was required to elute the title 
compound. Concentration of the eluent in the desired 
fractions gave 1.18 g (44%) of the alcohol as a light 
yellow, viscous oil. TLC analysis (1:4 ether:petroleum 
ether, bp 50°-110° C.) indicated the compound was 
essentially pure. 
IR (neat) 3150-3650 cm- 1; 1H NMR (DCCl3) ol.31 
[s, 3H, C(CH3)CH3], 1.32 [s, 3H, C(CH3)CH3], 1.45 [d, 
3H, CH(C:fl))], 2.36 (bs, lH, O-H), 4.81 [q, 1 H, 
CH(CH3)],6.71 [d, J=8 Hz, lH, H(7)], 7.08 [dd, J=8 
65 Hz, J = 1.9 Hz, lH, H(6)], 7.13 [d, J = 1.9 Hz, lH, H[(4)]; 
13C NMR (DCCb) ppm 25.1 [CH(CH3)], 27.5 
[C(CH3)2], 41.9 [C(CH3)2, 7.02 [C-OH], 84.7 [OCH2]; 
Ar.=._g [109.3, 119.5, 125.4, 136.~ 138.3, 158.6]. -
oil was vacuum distilled to give the cyclic ether (8.5 g, 
82%) as a colorless liquid: bp 48.2°-60.0° C./0.05-0.06 60 
mm [literature reports 62° -64° C./0.01 mm; see P. 
Gates, D. Baldwin, C. A. Wilson, and J. Gillon (Fison's 
Ltd.), U.S. Pat. No. 4,333,759; Chem. Abstr. 1982, 97, 
215978 p)]. TLC analysis [1:5 ethyl acetate:petroleum 
ether (bp 50°-110° C.)] indicated traces of two impur-
ties. IR(neat) 1197 cm- 1 (C-O); 1H NMR (DCCl3) 
81.3 l [2, 6H, C(CH)3)2], 4.24 (s, 2H, OCH2), 6.67 (d, lH, 
Ar-!!), 7.18-7.25(m, 2H, Ar-!!); 13C NMR (DCCl3) 
4,977,276 
22 21 
(DCCIJ) ol.29 [s, 6H, CH3(9,10)], 1.76-1.84 [m, 2H, 
~OH 
\V 
(43) H(3)], 4.14-4.20 [m, 2H, H(2)], 4.75-4.83 [dd, 2H, 
H(l2)], 5.54 [m, IH, H(ll)], 6.68-6.71 [d, IH, H(7)], 
6.88-6.91 [s, IH, H(5)], 7.07 [s, IH, H(5)], 7.60-8.00 [m, 
5 15H, Ar-!!]- The salt was used without further purifi-
cation. Other runs have given yields as high as 82%. 
(1-(2,3-Dihydro-3,3-dimethyl-5-benzofuranyl)ethyl]tri-
phenylphosphonium Bromide (44) 
A solution of the precursor alcohol (43) (0.28 g, 1.46 
mmol) in methanol (5 mL) was added dropwise (about 
10 
3 min.) under N2 to a stirred mixture of triphenylphos-
phine hydrobromide (0.50 g, 1.46 mmol) in methanol 
(10 mL). After 7 minutes, the mixture became a solution 15 
which was stirred at room temperature for 40 hours. 
Evaporation of the solvent resulted in foaming and gave 
a colorless solid. The solid was changed to a powder by 
stirring the suspension of crude (44) in ether for 4.5 
hours. After filtering the solid, the fine powder was 20 
partially dried (air) and finally dried by high vacuum 
(P2Os, 100° C.), to give 0.69 g (88%) of the phospho-
nium salt as a creamy white powder; mp 207°-212° C.; 
1H NMR (DCCl3) ol.14 [s, 3H, (CH3)CCH3], 1.19 [s, 
3H, (CH3)CC!!3], 1.82 (dd, 3H, CHCH3), 4.22 (s, 2H, 25 
OC!!2), 6.56 (m, IH, C!!CH3), 6.61 (ct, IH, Ar-H), 
6.85-6.98 (m, 2H, Ar-H), 7.64-7.92 [m, lili, 




7-[ 4,4-Dimethylchroman-6-yl]-3, 7-dimethyl-2,4, 6-hep-
tatrienoic acid (47) 
A solution of n-butyllithium (8.20 mL, 1.31M, 10.77 
mmol) in hexane was added dropwise under argon to a 
stirred suspension of the precursor phosphonium salt 
(5.99 g, 10.77 mmol) in dry ether (100 mL). The result-
ing dark reddish-brown mixture was stirred at room 
temp for 10 minutes. To this mixture was added a solu-
tion of ethyl 3-formyl-2-butenoate (1.54 g, 10.77 mmol) 
in dry ether (30 mL). After stirring for 2 hours at room 
temp, the mixture was filtered and the resultant solid 
was washed (ether 250 mL). The combined filtrates 
were then concentrated in vacuo to yield 2.40 g (68.4%) 
of crude ester. This ethyl ester was then subjected to 
(44) 
30 chromatography over silica gel using ethyl acetate:pe-
troleum ether (2%:98%). The middle fraction of ester 
(70 mg) was then saponified using KOH (1.20 g, 21.4 
mmol) in water (2 mL) and ethanol (80 mL). The proce-
dure involved protecting the mixture from light while it 
6-[(3-Triphenylphosphonyl)-1-methyl-1-propenyl]-4,4-
dimethylchroman (45) 
35 was stirred at 50° C. for 4 hours under N2. After cooling 
to 0° C., the final mixture was acidified with 6N HCl 
and the resulting mixture was extracted (HCCl3, 2 X 25 
mL). The extracts were washed with brine solution, 
A solution of 4,4-dimethylchroman-6-yl methyl ke-
40 
tone (5.44 g, 26.67 mmol) in dry ether (20 mL) was 
added dropwise under N2 to a stirred solution of vinyl-
magnesium bromide in THF ( 40 mL, 40 mmol). The 
mixture was _allowed to react for 3.5 hours and was then 45 
quenched with saturated, aqueous NR4Cl solution with 
cooling. The supernatant liquid was decanted .and the 
residue was washed (dry ether, 100X3). The combined 
organic washings were dried (Na2SO4) and then the 
solvent was evaporated in vacuo to five 7.07 g of crude 50 
vinyl alcohol shown below. This crude alcohol 
(45) 
55 
(7.07 g, 30.4 mmol) was dissolved in 30 mL of CH3OH 
and the solution was added to a cold solution of triphen- 60 
ylphosphine hydrobromide (10.45 g, 30.47 mmol) in 
CH3OH (30 mL). The resulting solution was kept at 
room temperature with stirring for 2.5 hours. When the 
solution was poured slowly into dry ether (550 mL), a 
precipitate formed and was filtered off and dried for 2 65 
hours under vacuum at room temp. The yield of the salt 
shown below was 9.14 g (61.5%); mp 261°-262° C.; IR 
(KBr) 2975 (C-H), 1667 (C=C) cm-I; IH NMR 
dried (Na2SO4, 15 min) and then evaporated. Yellow 
crystals of acid (47) were obtained and then were re-
crystallized (abs ethanol) to yield a final weight of 29 
mg (45.3%); mp 218°-218.5° c. IR (KBr) 3250-2500 
cm- 1 (O-H), 1680 (C=O) cm-1; 1H NMR (DCCl3) 
ol.35 [s, 6H, (CH3)z], 1.79-1.83 [t, 2H, H(3)], 2.20 [3H, 
CH3(12)], 2.32 [s, 3H, CH3(17)], 4.15-4.18 [t, 2H, H(2)], 
5.76 [s, IH, H(18)], 6.40-6.45 [d, IH, H(l5)], 6.53-6.57 
[d, IH, H(13)], 6.68-6.71 [d, IH, H(8)], 6.96-7.05 [dd, 
IH, H(l4)], 7.19-7.23 [dd, IH, H(7)], 7.41-7.42 [d, IH, 
H(5)]; 13C NMR ppm 13.43 [C(17)], 16.0 [C(12)], 30.3 
[C(4)], 30.8 [C(CH3)z], 38.87 [C(3)], 62.57 [C(2)], 115.5 
[C(8)], 116.5 [C(l8)], 123.5 [C(5)], 124.3 [C(7)], 131.1 
[C(l3)], 133.9 [C(l4)], 135.1 [C(6)], 151.5 [C(8a)], and 
167.9 [C(19)]. Other signals not assigned appeared at: 
119.2, 139.1, 151.5, and 153.2 ppm. Anal. Calcd for 




3,4-Dihydro-4,4-dimethyl-2H-l-benzopyran ( 48) 
A solution of2-methyl-4-phenoxy 2-butanol (41.10 g, 
288.33 mmol) in freshly distilled nitromethane (40 mL) 
23 
4,977,276 
was added dropwise under N2 to a stirred suspension of 
anhydrous AlCl3 (41.43 g, 308. l. mmol) in freshly dis-
tilled nitromethane (165 mL). After stirring at room 
temperature for an additional 24 hours, a solution of 6M 
HCI (425 mL) was added slowly. The resulting mixture 5 
was stirred for 10 minutes and diluted with ether (200 
mL). The layers were separated, and the organic layer 
was washed with H2O (200 mL), saturated NaHCO3 
(4X 150 mL), H2O (150 mL), and saturated solution of 
NaCl (2X 150 ml). After the solution was dried lO 
(MgSO4, 30 min), the solvent was removed (vacuum). 
Vacuum distillation of resulting dark brown oil gave 
27.96 rams (75.6%) of the pyran (48) as a colorless liq-
uid: bp 43°-44° C./0.2 mm [literature reports 93° C./10 15 
mm; see J. Cologne, E. Le Sech, and R. Marey Bull. 
Soc. Chim. France, 776 (1957)]; IH NMR (DCCl3) 81.27 
[s, 6H, (CH3)C], l.83 [m, 2H, CH2], 4.09 [m, 2H, OCH2], 
6.88-7.24[m, 4H, Ar-H]; 13CNMR (DCClJ) ppm 30.5 
[C(CH3)z], 31.1 [(CH3)2C], 37.7 [CH2], 63.0 [OCH2], 20 






A solution of the methyl ketone (49) (180 g, 88.1 
mmol) in anhydrous ether (80 mL) was added dropwise 
under N2 to a stirred suspension of LiAIH4 (5.01 g, 
132.27 mmol) in dry ether (315 mL). The mixture was 
heated at reflux for 24 hours. After cooling to room 
temperature, ethyl acetate (85 ml) was added dropwise 
to destroy the excess LiAlH4. A solution of 5% HCI 
(255 mL) was then added, and the resulting mixture was 
stirred for 5 minutes. The layers were separated, and the 
aqueous layer was washed (ether 3 x 150 mL). The 
combined organic layers were washed with 5% aque-
ous Na2CO3 (2X 100 mL) and water (150 mL) followed 
by a saturated NaCl solution (150 ml). After the solution 
was dried (MgS04, 30 min.) the solvent was removed 
leaving a yellow oil which solidified after scratching. 
Recrystallization (hexane) gave 15.25 grams (82.9%) of 
the alcohol (50) as a white solid: mp 71 ° -72° C. [litera-
ture reports 70°-71 ° C.; see K. M. Waugh, K. D. Berlin, 
4,4-Dimethylchroman-6-yl Methyl Ketone or 
l-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)e-
thanone ( 49) 
25 W. T. Ford, E. M. Holt, J.P. Carrol, P.R. Schomber, 
M. D. Thompson, and L. J. Schiff J. Med. Chem 28, 116 
(1985)]; IR (KBr) 3140-3640 cm-I (OH); IH NMR 
(DCCl3) 81.32 [s, 6H, (CH3)2C], 1.50 [d, 3H, CH3], 1.31 
[s, lH, OH], 4.20 [m, 2H--;- H(2)], 4.84 [q, lH, CHOH], 
30 6.76 [d, ill, H(8)], 7.07 [dd, lH, H(7)], 7.28 [d, lH, 
H(S)]; 13C NMR (DCCl3) ppm 24.9 [fH3], 30.6 [C(4)], 
31.0 [(CH3)2C], 37.6 [C(3)], 62.9 [C(2)], 70.2 [C(9)], 
116.8 [C(8)], 123.9, 124.2 [C(5), C(7)], 131.1, 137.6 Anhydrous AICl3 (2.99 g, 22.51 mmol) was added in 
small portions to 4,4-dimethylchroman (3.45 g, 21.30 
mmol) and acetyl chloride (1.51 mL, 21.30 mmol) in 
35 
CH3NO2 (30 mL) under N2. After stirring at room tem-
perature for 6 hours, 6M HCI (30 mL) was added 
slowly, and the resulting mixture was stirred for 10 
minutes. The mixture was diluted with ether (70 mL) 40 
and the layers were separated. The organic layer was 
washed with H2O (50 mL), saturated aqueous NaHCO3 
(4X40 mL), H2O (50 mL), and saturated solution of 
NaCl (50 mL). After the solution was dried (MgSO4, 30 
min), the solvent was removed to leave a dark, reddish 45 
brown oil. Vacuum distillation gave 3.09 g (89.03%) of 
the ketone as a pale yellow liquid: bp 94 ° -95° C./0.1 mm 
[literature reports 108°-112° C./0.01 mm; see K. M. 
Waugh, K. D. Berlin, W. T. Ford, E. M. Holt, J. P. 
Carrol, P. R. Schomber, M. D. Thompson, and L. J. 50 
Schiff J. Med. Chem., 28, 116 (1985)]; IR (neat) 
1675-1685 cm-I (C=O); IH NMR (DCCIJ) 81.38 [s, 
6H, (CH3)2C], l.84 [m, 2H, CH2], 2.52 [s, 3H, CH3C], 
4.26 [m-:-2H, CH2O], 6.82 [d, TH, H(8)], 7.71 [dd-:-rn, 
H(7)], 7.99 [d, ill, H(5)]; 13C NMR (DCCb) ppm 26.1 55 
[CH3], 30.5 [C(CH3)2], 30.6 [(CH3)2C], 37.0 [CH2], 63.3 
[CH2O], 116:7 [C(8)], 127.5 [C(5)], 127.9 [C(7)], 130.0, 
131.6 [C(4a), C(6), 157.8 [C(8a)], 196.4 [C=O]. Mass 
spectral data for C13H1sO2: m/e (M=) 204.1150; Found: 
[C(4a), C(6)], 152.9 [C(8a)]. 
(50) 
[1-4,4-Dimethylchroman-6-yl)ethyl]triphenylphos-
phonium Bromide or 
[1-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)e-
thyl]triphenylphosphonium Bromide (51) 
A solution of the alcohol precursor (50) (0.70 g, 3.4 
mmol) and triphenylphosphine hydrobromide (l.2 g, 3.5 
mmol) in methanol (30 mL) was stirred under N2 at 
room temperature for 24 hours. The solvent was re-
moved (vacuum), and the resulting oil was triturated 
repeatedly with dry ether until it solidified. The white 
solid was suspended and stirred in dry ether (30 mL) at 
room temperature under N2 for 4 hours, filtered, and 
204.1155. 60 
dried (110° C./2 mm) to give l.75 g (96.9%) of the salt 
as a white powder: mp 152°-156° C. (dee) [literature 
reports 149°-155° C.; see K. M. Waugh, K. D. Berlin, 
W. T. Ford, E. M. Holt, J.P. Carrol, P.R. Schomber, 
M. D. Thompson, and L. J. Schiff J. Med. Chem, 28, 116 
(49) (1985)]; IH NMR (DCCIJ) 81.08 [s, 3H, CH3], 1.14 [s, 
3H, CH3], l.76 [m, 2H, H(3)], l.83 [d, 3H, CHCH3], 4.16 
65 [m, 2H--:-H(2)], 6.3 [m, lH, CH+PPh3, Br-], 6.57[d, lH, 
H(8)], 6.67 [d, IH, H(7)], 7.74 [brs, lH, H(S)], 7.63-7.84 









dimethyl-2H- l-benzopyran-6-yl)propene (52) 10 
A solution of n-butyllithium in hexane (1.55M, 1.23 
mL, 1.88 mmol) was added dropwise under N2 to a 
stirred suspension of the precursor phosphonium salt 51 
(1 g, 1.88 mmol) in dry ether (20 mL). The resulting 15 
solution was cooled to - 78° C., and a solution of 5-
acetoxymethyl-2-furanaldehyde (0.316 g, 1.88 mmol) 
was added over a period of 1 minute. The solution was 
stirred for a few minutes at - 78° C. and then at room 
temperature for 24 hours. The mixture changed from 20 
reddish-brown to a pale brown color. After 24 hours, 
the reaction mixture was filtered. The resulting solid 
was washed with 45 mL of ether (anhydrous), and the 
filtrate was concentrated to give a yellow oil. This 25 
yellow oil was refrigerated for 24 hours and became a 
dark yellow solid. This solid was passed through 20 
grams of silica gel [column, (8X200 MM)]. The product 
was eluted with 300 mL of hexane:ethyl acetate (4:1) 
concentration of eluent gave a viscous oil from which 30 
yellow solid was obtained after keeping it in ice bath at 
0° C. for 5 hours. Recrystallization (hexane) gave 0.12 
grams (19%) of the ester (52) as a white crystaline solid: 
mp 80°-81° C. 1H NMR (DCCl3) ol.37 [s, 6H, H(9), 
H(lO)], 1.85 [m, 2H, H(3)], 2.1 [s, 3H, H(20)], 2.36 [s, 3H, 35 
H(12)], 4.20 [m, 2H, H(2)], 5.08 [s, 2H, H(18)], 6.31 [d, 
lH, J =3 Hz H(16)], 6.46 [d, lH, J = 3 Hz H(5)], 6.53 [s, 
lH, H(13)], 6.77 [d, lH, J =9 Hz, J =3 Hz H(8)], 7.21 
[dd, lH, H(7)], 7.39 [d, lH, H(15)]; 13C NMR (DCCl3) 
ppm 18.24 [C(12)], 20.94 [C(20)], 30.69 [C(4)], 31.06 40 
[C(9), C(lO)], 37.63 [C(3)], 58.31 [C(18)], 63.11 [C(2)], 
109.54 [C(16)], 114.15 [C(15)], 116.8 [C(8)], 124.36 
[C(S)], 124.77 [C(7)], 70.69 [C(19)], non-protonated and 
vinylic carbons [131.3, 135.6, 136.9, 147.7, 153.3, 154.6]. 45 
Mass spectral data for C21H2404: m/e (M=) 340.1674. 
Found: 340.1679. Anal. calcd. for C21H2404: C, 74.08; 








Acetone + TP A 1 
13-cis-retinoic 
acid+ TPA 
(38) + TPA 








*nmol CO2/30 min/mg protein 
Acetone 0.0 
Acetone+ TPA 0.0 
13-cis-retinoic 17 
acid+ TPA 
(40) + TPA 





0.00 ± 0.0 
0.90 ± 0.31 
0.1 ± 0.01 
0.1 ± 0.01 
0.0 ± 0.0 
0.00 ± 0.0 
1.67 ± 0.14 
0.14 ± 0.04 
0.97 ± 0.13 
1.4 ± 0.2 
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In the screening tests of the Table, the selected reti-
noids in 0.2 ml of acetone were applied 1 hour before 
the application of 10 nmole ofTPA to the shaved backs 
of mice; the mice where then sacrificed for ODC assay 
5 hours after TP A treatment. Epidermus was separated, 
homogenized, and centrifuged at 30,000X g. Soluble 
epidermal ODC activity was assayed. The retinoids 
were evaluated in three independent experiments (3 
groups of mice with 3 mice per group) and the results 
from the experiments were normalized (% inhibition) 
for comparison. As seen from the data, the ethyl ester of 
the thiochromanyl structure (39) had the strongest ac-
tivity. In comparison with 13-cis-retinoic acid as the 
standard, the ester (39) was more active while the acid 
form (38) was essentially equivalent in activity to the 
standard. In the experiments with trans-retinoic acid as 
the standard, the acid form of the chromanyl structure 
(47) was slightly less active than the standard. The re-
lated ester ( 40) with the large polar group was less 
active compared to the same control. Which standard is 
used appears to be relatively unimportant for determin-
ing activity in the assay, but the data presented in the 
Table identifies the standard for sake of clarity and 
accuracy of presentation. Thus, the presence of the 
heteroatom in these arotinoids has not eliminated bio-
logical activity. It is also clear that the acid in the simple 
55 esters are the most active regardless of whether sulfur 
oxygen is the heteroatom. Consequently, the nature of 
the terminus group is also important. 
In order to demonstrate and evaluate the biological 
activity of the heteroarotinoids according to the present 60 
invention, selected compounds were assayed either via 
analysis of the suppression of the 12-o-tetradeconoyl-
phorbol-13-acetate (TPA) induced synthesis of orni-
thine decarboxylase (ODC) in mouse skin or the induc-
tion of differentiation of human (HL-60) promylelo- 65 
cytic cells. In the ODC assay, either 13-cis-retinoic acid 
or trans-retinoic acid was employed. The following 
Table summarizes the result of the ODC assays. 
In order to evaluate the efficacy of the heteroaroti-
noids to induce HL-60 cell differentiation along the 
granulocytic maturation pathway, human HL-60 cells 
were grown in a serum-free medium consisting of 
HRPMI 1640 supplemented with 10 nM 4-(2-hydroxye-
thyl)-l-piperazineethane sulfonic acid, 5 ug of in-
sulin/mL, and 5 ug of transferrin/mL. These mature 
cells, unlike the uninduced HL-60, produced superoxide 
anion when simulated with an appropriate agent, such 
as TPA. The ability of the individual cells to produce 
superoxide can be measured by incubating cells with the 
4,977,276 
28 27 
water-soluble yellow dye, nitroblue tetrazolium (NBT). 
NBT is reduced to a water-insoluble blue-black forma-
zan by superoxide. This formazan precipitate is associ-
ated with those cells that produce superoxide. Thus, the 
percentage of cells in a population that produce super- 5 
oxide (NET-positive cells) can be enumerated under a 
light microscope. 
The retinoids were dissolved in DMSO or ethanol 
and diluted into the culture medium so that the final 
concentration of the solvent did not exceed 0.1 %, a 10 
concentration that has no effect on differentiation. After 
incubation for 4 days at 37° C. in a humidified atmo-
sphere of 5% CO2 and air, the capacity of the cells to 
reduce NBT was determined. Viable cells (106) were 
harvested by centrifugation and suspended in 0.5 mL of 15 
RPMI 1640 containing 20% fetal bovine serum. This 
cell suspension was mixed with an equal volume of 
phosphate buffered saline containing 1 mg ofNBT/mL 
and 200 mg of TP A/mL. The reaction mixture was 
incubated at 37° C. for 25 minutes, and the reaction was 20 
terminated by cooling in an ice water bath. Cytospin 
slides were prepared from a portion of this reaction 
mixture and stained with Wright-Giemsa. A minimum 
of 200 cells were counted under light microscopy to 
determine the percentage of cells with cell-associated 25 
formazan. 
The dose-response of HL-60 to trans-retinoic acid, 
the thiochromanyl acid (38) and the chromanyl acid 
(47) is shown in FIG. 1. The concentration of retinoid 
effective in achieving a half-maximal response (EDso) is 30 
41 nM for trans-retinoic acid, 72 nM for (38), and 200 
nM for (47). Based on the above observed relative activ-
ities, it appears as if the oxygen-substituted derivatives 
are of a slightly less activity than the sulfur-substituted 
derivatives. 35 
The Human Tumor Cell Line Bioassay (HTCL) has 
been conducted in a manner similar to the procedure 
described by Alley and co-workers (Cancer Research 
1988, 48, 589-601). A panel of 4 tumor cell lines were 
grown in microliter plates and various concentrations of 40 
the test compounds were added to the wells. After 4 
days, the number of viable cells were measured in terms 
of production of formazin after incubation with MIT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide]. Formazin production is directly proportional 45 
to the viable cell number/well and can be measured 
spectrophotometrically after solubilization. 
The cell lines used in the HTCL assay were A-549 
(lung adenocarcinoma), HT-29 (colon adenocarci-
noma), MCF-7 (breast adenocarcinoma), and RPMI- 50 
7951 (melanoma). With the exception of HT-29, these 
cells have been adopted to grow in BlO medium which 
consists of Eagle's Minimum Essential Medium supple-
mented with 1.5 X the essential amino acids, 2 X the 
non-essential amino acids, 1.5 X vitamins, 1 X L-gluta- 55 
mine, 10% calf bovine serum (CBS), and 1 X antibiotic 
solution (PSF) consisting of 50 U/mL of penicillin, 50 
ug/mL of streptomycin sulfate, and 50 ug/mL of am-
photericin B. HT-29 cells were grown in McCoy's 5A 
medium supplemented with 10% CBS and 1 X PSF. 60 
Stock cultures of cells were routinely grown in 25 cm2 
flasks (T-25) and passaged on a weekly basis. Cells were 
passaged by washing twice with phosphate buffered 
saline (PBS) and once with a 0.005% trypsin-0.01 % 
EDT A solution. Trypsin-EDT A solution was added 65 
and the flask was allowed to incubate for 2-5 minutes 
until the cells were detached. After detaching from the 
flask, the cells were resuspended in their appropriate 
medium, counted on a Coulter Counter (ZBI), and an 
aliquot was transferred to new T-25 flasks. The remain-
ing cells were used to set up the assay in 96 well microli-
ter plates. Either 3,000 (HT-29, MCF-7) or 2,000 (A-
549, RPMI-7951) cells were added to the wells in a 
96-well microliter plate in 0.2 mL of medium (Day 1). 
On Day 2, the compounds were resuspended at 1 or 2 
mg/mL in acetone, and the compounds were serially 
diluted 10 or 5 fold in PBS and 20 uL of each dilution 
starting at 100 or 200 ug/mL was added to 4 wells of the 
microliter plate. Doxyrubicin was used as a positive 
control compound. On Day 7, 20 uL of MIT (2 
mg/mL) was added to each of the wells. The plates 
were then incubated at 37° C. for 4 hours. After incuba-
tion, the medium and MIT were removed by aspiration 
and 100 uL of DMSO was added to solubilize the for-
mazin product. The plates were read on a Dynatech 700 
plate reader at 540 nm, and the data were collected on 
an IBM PC. The data were graphed and the EDso was 
determined from the graph. The EDsois the dose of the 
test compound that shows an O.D. reading of 50% of 
the untested, control value. The data is summarized in 
the following Table. 
EOsQ Values (icg/mL) 
Compound Cell Line: A-549 HT-29 RPMI-7951 MCF-7 
Trans•retinoic >10 1 2 NOT2 >10 
Acid 40 20 30 40 
A NOT 5 NOT NOT 
40 60 80 100 
B NOT > IO NOT NOT 
40 70 84 100 
C NOT > IO NOT NOT 
20 100 
0 NOT 5 NOT NOT 
30 100 
Ooxyrubicin 0.5 0.3 0.2 0.5 
(Adriamycin) 0.2 0.6 0.1 2.0 
1Sensitivity was detected but the ED~o was above the highest concentration tested. 
2NDT: No detectable toxicity 








In the HTCL bioassay, the smaller the number of 
viable cells at the end of the experiment ( determined by 
measurement of the color intensity via spectrophotome-
try), the more active is the compound. Consequently, 
the small numbers for compounds A and D (5 and 5, 5 
respectively) are from separate experiments and indi-
cated good activity for both compounds. Compounds B 
and C exhibited slightly reduced activity in this same 
cell line. Thus, there is a spectrum of activity possible 
10 with these compounds which have potential as antitu-
mor agents. This is especially important since the treat-
ment of colon cancers is particularly difficult and 






The screens in the other cell lines were less impres- 15 
sive compared to the standard tran-retinoic acid and 
Doxyrubicin. Nevertheless, the above data strongly 
support the potential useful activity with high degree of 
specificity of action in the colon tumor cell line. This 
work was performed in collaboration at the Depart-
ment of Pharmacology at the Ohio State University 
under the direction of Dean John Cassidy. 
where Xis Sor O; and R is -H, -OH, -OCH3 or 
20 
-OC2Hs. 
2. A heteroarotinoid of claim 1 where X is S and R is 
-H. 
Having thus described and exemplified the preferred 
embodiments with a certain degree of particularity, it is 
manifest that many changes can be made within the 
details of operation, operating parameters, and steps for 
synthesizing and using the heteroarotinoids according 
to the present invention without departing from the 
spirit and scope of this invention. Therefore, it is to be 
understood that the invention is not limited to the em-
bodiments set forth herein for purposes of exemplifica-
tion, but is to be limited only by the scope of the at-
tached claims, including the full range of equivalents to 
which each step thereof is entitled. 
We claim: 
1. A heteroarotinoid characterized by the formulae: 
3. A heteroarotinoid of claim 1 where X is S and R is 
-OH. 
4. A heteroarotinoid of claim 1 where X is S and R is 
25 
-OCH3. 
5. A heteroarotinoid of claim 1 where X is S and R is 
-OC2Hs. 
6. A heteroarotinoid of claim 1 where Xis O and R is 
-H. 
30 7. A heteroarotinoid of claim 1 where Xis O and R is 
-OH. 
8. A heteroarotinoid of claim 1 where Xis O and R is 
-OCH3. 
9. A heteroarotinoid of claim 1 where X is O and R is 
35 
-OC2Hs. 
* * * * * 
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